Glycoprotein targeted therapeutics: A new era of anti-herpes simplex virus-1 therapeutics

Reviews in Medical Virology

Volumn 23, Issue 3, 2013, Pages 194-208

  Antoine, Thessicar E ^a   Park, Paul J ^a   Shukla, Deepak ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BEHENYL ALCOHOL; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; GLYCOPROTEIN B; GLYCOPROTEIN D; NECTIN 1; PROTEIN C; PROTEIN VP16; RNA POLYMERASE II; THYMIDINE KINASE; VALACICLOVIR; VIRUS DNA; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CELL NUCLEUS; DNA REPLICATION; DNA SYNTHESIS; GENE MUTATION; GENETIC TRANSCRIPTION; HERPES LABIALIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 1 INFECTION; HERPES VIRUS INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; PHOSPHORYLATION; PROTEIN FUNCTION; REVIEW; SEQUENCE HOMOLOGY; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS PATHOGENESIS;

ANTIVIRAL AGENTS; HERPESVIRUS 1, HUMAN; HUMANS; RECEPTORS, VIRUS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84877619850     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1740     Document Type: Review

References (142)

1. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA: The Journal of the American Medical Association 2006; 296(8): 964-973.
2. Rubicz R, Leach CT, Kraig E, et al. Genetic factors influence serological measures of common infections. Human Heredity 2011; 72(2): 133-141.
3. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. Journal of the American Academy of Dermatology 2007; 57(5): 737-763; quiz 764-736.
4. Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrobial Agents and Chemotherapy 1997; 41(7): 1521-1530.
5. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. The Journal of Infectious Diseases 2002; 186(Suppl 1): S3-S28.
6. Bedadala GR, Palem JR, Graham L, Hill JM, McFerrin HE, Hsia SC. Lytic HSV-1 infection induces the multifunctional transcription factor early growth response-1 (EGR-1) in rabbit corneal cells. Virology Journal 2011; 8: 262.
7. Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF. Herpes simplex. Pediatrics in Review 2009; 30(4): 119-129; quiz 130.
8. Stevens JG, Nesburn AB, Cook ML. Latent herpes simplex virus from trigeminal ganglia of rabbits with recurrent eye infection. Nature: New Biology 1972; 235(59): 216-217.
9. Stevens JG, Cook ML. Latent infections induced by herpes simplex viruses. Cancer Research 1973; 33(6): 1399-1401.
10. Wechsler SL, Nesburn AB, Watson R, Slanina SM, Ghiasi H. Fine mapping of the latency-related gene of herpes simplex virus type 1: alternative splicing produces distinct latency-related RNAs containing open reading frames. Journal of Virology 1988; 62(11): 4051-4058.
11. Perng GC, Dunkel EC, Geary PA, et al. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. Journal of Virology 1994; 68(12): 8045-8055.
12. Perng GC, Slanina SM, Yukht A, Ghiasi H, Nesburn AB, Wechsler SL. The latency-associated transcript gene enhances establishment of herpes simplex virus type 1 latency in rabbits. Journal of Virology 2000; 74(4): 1885-1891.
13. Cook ML, Bastone VB, Stevens JG. Evidence that neurons harbor latent herpes simplex virus. Infection and Immunity 1974; 9(5): 946-951.
14. Zwaagstra JC, Ghiasi H, Nesburn AB, Wechsler SL. Identification of a major regulatory sequence in the latency associated transcript (LAT) promoter of herpes simplex virus type 1 (HSV-1). Virology 1991; 182(1): 287-297.
15. Rautemaa R, Helander T, Meri S. Herpes simplex virus 1 infected neuronal and skin cells differ in their susceptibility to complement attack. Immunology 2002; 106(3): 404-411.
16. Perng GC, Jones C. Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. Interdisciplinary Perspectives on Infectious Diseases 2010; 2010: 262415.
17. Ahmed M, Fraser NW. Herpes simplex virus type 1 2-kilobase latency-associated transcript intron associates with ribosomal proteins and splicing factors. Journal of Virology 2001; 75(24): 12070-12080.
18. Al-Dujaili LJ, Clerkin PP, Clement C, et al. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiology 2011; 6(8): 877-907.
19. Patel R. Antiviral agents for the prevention of the sexual transmission of herpes simplex in discordant couples. Current Opinion in Infectious Diseases 2004; 17(1): 45-48.
20. Sacks SL, Griffiths PD, Corey L, et al. HSV-2 transmission. Antiviral Research 2004; 63(Suppl 1): S27-S35.
21. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. The New England Journal of Medicine 2004; 350(1): 11-20.
22. Maclean CA. HSV entry and spread. Methods in Molecular Medicine 1998; 10: 9-18.
23. Dohner K, Wolfstein A, Prank U, et al. Function of dynein and dynactin in herpes simplex virus capsid transport. Molecular Biology of the Cell 2002; 13(8): 2795-2809.
24. Garber DA, Beverley SM, Coen DM. Demonstration of circularization of herpes simplex virus DNA following infection using pulsed field gel electrophoresis. Virology 1993; 197(1): 459-462.
25. Jackson SA, DeLuca NA. Relationship of herpes simplex virus genome configuration to productive and persistent infections. Proceedings of the National Academy of Sciences of the United States of America 2003; 100(13): 7871-7876.
26. Boehmer PE, Nimonkar AV. Herpes virus replication. IUBMB Life 2003; 55(1): 13-22.
27. LaBoissiere S, O'Hare P. Analysis of HCF, the cellular cofactor of VP16, in herpes simplex virus-infected cells. Journal of Virology 2000; 74(1): 99-109.
28. Grondin B, DeLuca N. Herpes simplex virus type 1 ICP4 promotes transcription preinitiation complex formation by enhancing the binding of TFIID to DNA. Journal of Virology 2000; 74(24): 11504-11510.
29. Long MC, Leong V, Schaffer PA, Spencer CA, Rice SA. ICP22 and the UL13 protein kinase are both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II. Journal of Virology 1999; 73(7): 5593-5604.
30. Spencer CA, Dahmus ME, Rice SA. Repression of host RNA polymerase II transcription by herpes simplex virus type 1. Journal of Virology 1997; 71(3): 2031-2040.
31. Rice SA, Su LS, Knipe DM. Herpes simplex virus alpha protein ICP27 possesses separable positive and negative regulatory activities. Journal of Virology 1989; 63(8): 3399-3407.
32. Cai W, Schaffer PA. Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells. Journal of Virology 1992; 66(5): 2904-2915.
33. Kwong AD, Frenkel N. Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proceedings of the National Academy of Sciences of the United States of America 1987; 84(7): 1926-1930.
34. Liptak LM, Uprichard SL, Knipe DM. Functional order of assembly of herpes simplex virus DNA replication proteins into prereplicative site structures. Journal of Virology 1996; 70(3): 1759-1767.
35. Lukonis CJ, Burkham J, Weller SK. Herpes simplex virus type 1 prereplicative sites are a heterogeneous population: only a subset are likely to be precursors to replication compartments. Journal of Virology 1997; 71(6): 4771-4781.
36. He X, Lehman IR. An initial ATP-independent step in the unwinding of a herpes simplex virus type I origin of replication by a complex of the viral origin-binding protein and single-strand DNA-binding protein. Proceedings of the National Academy of Sciences of the United States of America 2001; 98(6): 3024-3028.
37. Makhov AM, Boehmer PE, Lehman IR, Griffith JD. The herpes simplex virus type 1 origin-binding protein carries out origin specific DNA unwinding and forms stem-loop structures. The EMBO Journal 1996; 15(7): 1742-1750.
38. He X, Lehman IR. Unwinding of a herpes simplex virus type 1 origin of replication (Ori(S)) by a complex of the viral origin binding protein and the single-stranded DNA binding protein. Journal of Virology 2000; 74(12): 5726-5728.
39. Chang L, Godinez WJ, Kim IH, et al. Herpesviral replication compartments move and coalesce at nuclear speckles to enhance export of viral late mRNA. Proceedings of the National Academy of Sciences of the United States of America 2011; 108(21): E136-E144.
40. Hernandez TR, Lehman IR. Functional interaction between the herpes simplex-1 DNA polymerase and UL42 protein. The Journal of Biological Chemistry 1990; 265(19): 11227-11232.
41. Gottlieb J, Marcy AI, Coen DM, Challberg MD. The herpes simplex virus type 1 UL42 gene product: a subunit of DNA polymerase that functions to increase processivity. Journal of Virology 1990; 64(12): 5976-5987.
42. Song L, Chaudhuri M, Knopf CW, Parris DS. Contribution of the 3'- to 5'-exonuclease activity of herpes simplex virus type 1 DNA polymerase to the fidelity of DNA synthesis. The Journal of Biological Chemistry 2004; 279(18): 18535-18543.
43. Furman PA, de Miranda P, St Clair MH, Elion GB. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrobial Agents and Chemotherapy 1981; 20(4): 518-524.
44. Sauerbrei A, Deinhardt S, Zell R, Wutzler P. Testing of herpes simplex virus for resistance to antiviral drugs. Virulence 2010; 1(6): 555-557.
45. Derse D, Cheng YC, Furman PA, St Clair MH, Elion GB. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. Journal of Biological Chemistry 1981; 256(22): 11447-11451.
46. Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA: The Journal of the American Medical Association 1990; 263(12): 1662-1664.
47. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Research 1995; 28(4): 281-290.
48. Ormrod D, Scott LJ, Perry CM. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 2000; 59(4): 839-863.
49. Granero GE, Amidon GL. Stability of valacyclovir: implications for its oral bioavailability. International Journal of Pharmaceutics 2006; 317(1): 14-18.
50. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clinical Pharmacology and Therapeutics 1993; 54(6): 595-605.
51. Sinko PJ, Balimane PV. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharmaceutics & Drug Disposition 1998; 19(4): 209-217.
52. Chakrabarty A, Anderson NJ, Beutner R, Tyring SK. Valacyclovir for the management of herpes viral infections. Skin Therapy Letter 2005; 10(1): 1-4.
53. Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50(2): 396-415.
54. Degreef H, Andrejevic L, Aoki F, et al. Famciclovir, a new oral antiherpes drug - results of the first controlled clinical-study demonstrating its efficacy and safety in the treatment of uncomplicated herpes-zoster in immunocompetent patients. International Journal of Antimicrobial Agents 1994; 4(4): 241-246.
55. Chakrabarty A, Tyring SK, Beutner K, Rauser M. Recent clinical experience with famciclovir--a " third generation" nucleoside prodrug. Antiviral Chemistry & Chemotherapy 2004; 15(5): 251-253.
56. Simpson D, Lyseng-Williamson KA. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 2006; 66(18): 2397-2416.
57. Kang SH, Chua-Gocheco A, Bozzo P, Einarson A. Safety of antiviral medication for the treatment of herpes during pregnancy. Canadian family physician Medecin de famille canadien 2011; 57(4): 427-428.
58. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrobial Agents and Chemotherapy 2011; 55(2): 459-472.
59. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Reviews of Infectious Diseases 1988; 10(Suppl 3): S490-S494.
60. Castela N, Vermerie N, Chast F, et al. Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. Journal of Ocular Pharmacology 1994; 10(2): 439-451.
61. Shiota H, Naito T, Mimura Y. Anti-herpes simplex virus (HSV) effect of 9-(1, 3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea. Current Eye Research 1987; 6(1): 241-245.
62. Hoh HB, Hurley C, Claoue C, et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. The British Journal of Ophthalmology 1996; 80(2): 140-143.
63. Majumdar S, Nashed YE, Patel K, et al. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. Journal of Ocular Pharmacology and Therapeutics: The Official Journal of the Association for Ocular Pharmacology and Therapeutics 2005; 21(6): 463-474.
64. Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. The American Journal of Medicine 1992; 92(2A): 3S-7S.
65. Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. Journal of Clinical Microbiology 2004; 42(1): 242-249.
66. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS clinical trials group. The New England Journal of Medicine 1991; 325(8): 551-555.
67. Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrobial Agents and Chemotherapy 1997; 41(3): 594-599.
68. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clinical Microbiology Reviews 2003; 16(4): 569-596.
69. Cihlar T, Chen MS. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Molecular Pharmacology 1996; 50(6): 1502-1510.
70. Mendel DB, Barkhimer DB, Chen MS. Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrobial Agents and Chemotherapy 1995; 39(9): 2120-2122.
71. Muluneh B, Dean A, Armistead P, Khan T. Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient. Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners 2012. DOI: 10.1177/1078155212448408.
72. Kriebs JM. Understanding herpes simplex virus: transmission, diagnosis, and considerations in pregnancy management. Journal of Midwifery & Women's Health 2008; 53(3): 202-208.
73. Baker DA. Consequences of herpes simplex virus in pregnancy and their prevention. Current Opinion in Infectious Diseases 2007; 20(1): 73-76.
74. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists, number 57, November 2004. Gynecologic herpes simplex virus infections. Obstetrics and Gynecology; 104(5 Pt 1): 1111-1118.
75. Wojcechowskyj JA, Doms RW. A potent, broad-spectrum antiviral agent that targets viral membranes. Viruses 2010; 2(5): 1106-1109.
76. Pope LE, Marcelletti JF, Katz LR, et al. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Research 1998; 40(1-2): 85-94.
77. Katz DH, Marcelletti JF, Khalil MH, Pope LE, Katz LR. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proceedings of the National Academy of Sciences of the United States of America 1991; 88(23): 10825-10829.
78. Leung DT, Sacks SL. Docosanol: a topical antiviral for herpes labialis. Expert Opinion on Pharmacotherapy 2004; 5(12): 2567-2571.
79. Wilson SS, Fakioglu E, Herold BC. Novel approaches in fighting herpes simplex virus infections. Expert Review of Anti-Infective Therapy 2009; 7(5): 559-568.
80. Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot D, Morfin F. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrobial Agents and Chemotherapy 2005; 49(3): 1055-1059.
81. Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot D, Morfin F. Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study. Antiviral Research 2007; 73(2): 147-150.
82. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clinical Microbiology Reviews 2003; 16(1): 114-128.
83. Russell DB, Tabrizi SN, Russell JM, Garland SM. Seroprevalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting. Journal of Clinical Virology 2001; 22(3): 305-313.
84. Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Archives of Dermatology 1999; 135(11): 1393-1397.
85. Hu K, He X, Yu F, et al. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis. Immunological Investigations 2011; 40(3): 265-278.
86. Yu H, Liu ZT, Lv R, Zhang WQ. Antiviral activity of recombinant cyanovirin-N against HSV-1. Virologica Sinica 2010; 25(6): 432-439.
87. Mishra YK, Adelung R, Rohl C, Shukla D, Spors F, Tiwari V. Virostatic potential of micro-nano filopodia-like ZnO structures against herpes simplex virus-1. Antiviral Research 2011; 92(2): 305-312.
88. Diefenbach RJ, Miranda-Saksena M, Douglas MW, Cunningham AL. Transport and egress of herpes simplex virus in neurons. Reviews in Medical Virology 2008; 18(1): 35-51.
89. Mettenleiter TC. Budding events in herpesvirus morphogenesis. Virus Research 2004; 106(2): 167-180.
90. Campadelli-Fiume G, Cocchi F, Menotti L, Lopez M. The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Reviews in Medical Virology 2000; 10(5): 305-319.
91. Rao P, Pham HT, Kulkarni A, et al. Herpes simplex virus 1 glycoprotein B and US3 collaborate to inhibit CD1d antigen presentation and NKT cell function. Journal of Virology 2011; 85(16): 8093-8104.
92. Chouljenko DV, Kim IJ, Chouljenko VN, Subramanian R, Walker JD, Kousoulas KG. Functional hierarchy of herpes simplex virus 1 viral glycoproteins in cytoplasmic virion envelopment and egress. Journal of Virology 2012; 86(8): 4262-4270.
93. Frampton AR Jr., Goins WF, Nakano K, Burton EA, Glorioso JC. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Therapy 2005; 12(11): 891-901.
94. Turner A, Bruun B, Minson T, Browne H. Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. Journal of Virology 1998; 72(1): 873-875.
95. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, Cohen GH. Herpes virus fusion and entry: a story with many characters. Viruses 2012; 4(5): 800-832.
96. Shukla D, Liu J, Blaiklock P, et al. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999; 99(1): 13-22.
97. Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS Journal 2009; 276(24): 7228-7236.
98. Gerber SI, Belval BJ, Herold BC. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism. Virology 1995; 214(1): 29-39.
99. Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. The Journal of Cell Biology 1992; 116(5): 1273-1281.
100. Arii J, Goto H, Suenaga T, et al. Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1. Nature 2010; 467(7317): 859-862.
101. Chowdhury S, Naderi M, Chouljenko VN, Walker JD, Kousoulas KG. Amino acid differences in glycoproteins B (gB), C (gC), H (gH) and L (gL) are associated with enhanced herpes simplex virus type-1 (McKrae) entry via the paired immunoglobulin-like type-2 receptor alpha. Virology Journal 2012; 9: 112.
102. Bourne N, Bravo FJ, Francotte M, et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. The Journal of Infectious Diseases 2003; 187(4): 542-549.
103. Cai WH, Gu B, Person S. Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. Journal of Virology 1988; 62(8): 2596-2604.
104. Cairns TM, Whitbeck JC, Lou H, et al. Capturing the herpes simplex virus core fusion complex (gB-gH/gL) in an acidic environment. Journal of Virology 2011; 85(13): 6175-6184.
105. Atanasiu D, Whitbeck JC, de Leon MP, et al. Bimolecular complementation defines functional regions of herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. Journal of Virology 2010; 84(8): 3825-3834.
106. Galdiero S, Vitiello M, D'Isanto M, et al. The identification and characterization of fusogenic domains in herpes virus glycoprotein B molecules. Chembiochem 2008; 9(5): 758-767.
107. Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR. Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection. Antimicrobial Agents and Chemotherapy 2009; 53(3): 987-996.
108. Usatine RP, Tinitigan R. Nongenital herpes simplex virus. American Family Physician 2010; 82(9): 1075-1082.
109. Yasin B, Wang W, Pang M, et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. Journal of Virology 2004; 78(10): 5147-5156.
110. Brandt CR, Akkarawongsa R, Altmann S, et al. Evaluation of a theta-defensin in a murine model of herpes simplex virus type 1 keratitis. Investigative Ophthalmology & Visual Science 2007; 48(11): 5118-5124.
111. Shogan B, Kruse L, Mulamba GB, Hu A, Coen DM. Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B. Journal of Virology 2006; 80(10): 4740-4747.
112. Dix RD, Pereira L, Baringer JR. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infection and Immunity 1981; 34(1): 192-199.
113. Dix RD. Glycoprotein gB of herpes simplex virus expresses type-common and type-specific antigenic determinants in vivo. Journal of Medical Virology 1990; 30(3): 192-195.
114. Eis-Hubinger AM, Mohr K, Schneweis KE. Different mechanisms of protection by monoclonal and polyclonal antibodies during the course of herpes simplex virus infection. Intervirology 1991; 32(6): 351-360.
115. Krawczyk A, Krauss J, Eis-Hubinger AM, et al. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. Journal of Virology 2011; 85(4): 1793-1803.
116. Nicola AV, Willis SH, Naidoo NN, Eisenberg RJ, Cohen GH. Structure-function analysis of soluble forms of herpes simplex virus glycoprotein D. Journal of Virology 1996; 70(6): 3815-3822.
117. Subramanian RP, Geraghty RJ: Herpes simplex virus type 1 mediates fusion through a hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B. Proceedings of the National Academy of Sciences of the United States of America 2007; 104(8): 2903-2908.
118. Whitbeck JC, Peng C, Lou H, et al. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. Journal of Virology 1997; 71(8): 6083-6093.
119. Whitbeck JC, Muggeridge MI, Rux AH, et al. The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain. Journal of Virology 1999; 73(12): 9879-9890.
120. Tiwari V, Liu J, Valyi-Nagy T, Shukla D. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. Journal of Biological Chemistry 2011; 286(28): 25406-25415.
121. Krepstakies M, Lucifora J, Nagel CH, et al. A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. The Journal of Infectious Diseases 2012; 205(11): 1654-1664.
122. Krummenacher C, Rux AH, Whitbeck JC, et al. The first immunoglobulin-like domain of HveC is sufficient to bind herpes simplex virus gD with full affinity, while the third domain is involved in oligomerization of HveC. Journal of Virology 1999; 73(10): 8127-8137.
123. Nicola AV, Ponce de Leon M, Xu R, et al. Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM. Journal of Virology 1998; 72(5): 3595-3601.
124. Lazear E, Whitbeck JC, Ponce-de-Leon M, et al. Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization. Journal of Virology 2012; 86(3): 1563-1576.
125. Valimaa H, Tenovuo J, Waris M, Hukkanen V. Human lactoferrin but not lysozyme neutralizes HSV-1 and inhibits HSV-1 replication and cell-to-cell spread. Virology Journal 2009; 6: 53.
126. Valori CF, Ning K, Wyles M, Azzouz M. Development and applications of non-HIV-based lentiviral vectors in neurological disorders. Current Gene Therapy 2008; 8(6): 406-418.
127. St Vincent MR, Colpitts CC, Ustinov AV, et al. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proceedings of the National Academy of Sciences of the United States of America 2010; 107(40): 17339-17344.
128. Dean HJ, Terhune SS, Shieh MT, Susmarski N, Spear PG. Single amino acid substitutions in gD of herpes simplex virus 1 confer resistance to gD-mediated interference and cause cell-type-dependent alterations in infectivity. Virology 1994; 199(1): 67-80.
129. O'Keefe BR, Shenoy SR, Xie D, et al. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. Molecular Pharmacology 2000; 58(5): 982-992.
130. Bolmstedt AJ, O'Keefe BR, Shenoy SR, McMahon JB, Boyd MR. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Molecular Pharmacology 2001; 59(5): 949-954.
131. Shenoy SR, O'Keefe BR, Bolmstedt AJ, Cartner LK, Boyd MR. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. Journal of Pharmacology and Experimental Therapeutics 2001; 297(2): 704-710.
132. Tiwari V, Shukla SY, Shukla D. A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion. Antiviral Research 2009; 84(1): 67-75.
133. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Research and Human Retroviruses 2004; 20(1): 11-18.
134. Lin LT, Chen TY, Chung CY, et al. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. Journal of Virology 2011; 85(9): 4386-4398.
135. Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrobial Agents and Chemotherapy 1991; 35(4): 726-729.
136. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrobial Agents and Chemotherapy 2002; 46(1): 245-247.
137. Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, Scalise G. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. Journal of Antimicrobial Chemotherapy 1998; 41(1): 59-65.
138. Barchiesi F, Gallo D, Caselli F, et al. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. Journal of Antimicrobial Chemotherapy 1999; 44(1): 65-70.
139. Sondak VK, Korn EL, Kern DH. In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. International Journal of Cell Cloning 1988; 6(6): 378-391.
140. Sondak VK, Korn EL, Morton DL, Kern DH. Testing chemotherapeutic combinations in the human tumor colony--forming assay. Journal of Surgical Oncology 1988; 37(3): 156-160.
141. van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. British Journal of Cancer 1999; 80(7): 981-990.
142. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrobial Agents and Chemotherapy 2011; 55(5): 1831-1842.